Cognitive Behavioral Therapy for PTSD and Heart Disease Risk

This study is looking at how a type of talk therapy called Cognitive Processing Therapy (CPT) might help people with Posttraumatic Stress Disorder (PTSD) who are also at risk for heart disease. CPT is a standard treatment for PTSD that involves 12 weekly sessions to help you change unhelpful thoughts related to trauma. Researchers want to see if CPT can reduce inflammation in your arteries and improve your heart rate variability (how much your heart rate changes between beats), which are both signs of heart disease risk. You might be able to join if you are 18-65 years old, have PTSD symptoms, and show signs of early heart disease. This study is currently recruiting 30 participants.

Study design
This is a randomized controlled trial with 30 participants. You would be randomly assigned to either receive CPT or be in a waitlist control group.
What's involved
You would have a screening visit, a baseline visit with surveys, brain and peripheral imaging, and heart function tests. If assigned to CPT, you would have 12 telehealth sessions, followed by a post-treatment visit with the same tests.
Compensation
Not stated in the trial record.
Follow-up
Your arterial inflammation and heart rate variability will be measured at baseline and again at 12 weeks after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06429293

Impact of Cognitive Behavioral Therapy on PTSD-CVD Link

Recruiting
NAAges 18–65InterventionalTreatment
Massachusetts General Hospital
~30 participants
Updated 2025-09-25 on ClinicalTrials.gov
What's tested:Cognitive processing therapy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Arterial inflammation
Measured over Baseline and 12-weeks
+1 more outcome measured
Posttraumatic Stress Disorder
1 sites across 1 states
Massachusetts1

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

age 18-65 years (upper limit chosen to optimize changes in brain activation that diminish with age);
criterion A trauma exposure and PTSD symptoms (clinically significant symptoms in at least two symptom clusters);
subclinical atherosclerotic CVD (e.g., coronary, cerebrovascular, or peripheral arterial plaque or calcifications on imaging), clinical atherosclerotic CVD (e.g., myocardial infarction or revascularization), or increased risk for atherosclerotic CVD (i.e., \>2 of hypertension, diabetes mellitus, hyperlipidemia, and active smoking) ability to understand and sign informed consent
fluent English speaker.

Exclusion

history of stroke, brain surgery, seizure
use of certain CVD medications (e.g., beta-blockers, high-intensity statins \[e.g., rosuvastatin 20/40 mg and atorvastatin 40/80 mg\], PCSK-9 inhibitors);
psychiatric or cardiovascular medication change within 4 weeks (i.e., stable regimen is allowed);
currently in PTSD therapy;
neurological or systemic inflammatory disease/current anti-inflammatory therapy;
moderate/severe alcohol/substance use disorder;
current mania/psychosis;
weight \>300 lbs., claustrophobia, pregnancy, metal implants that are incompatible with magnetic resonance imaging (MRI), or uncontrolled hyperglycemia (for imaging);
significant radiation exposure (\>2 nuclear tests, computed tomography images, or fluoroscopic procedures) for research purposes during the preceding 12-months.
  • Arterial inflammationBaseline and 12-weeks

    Measured via FDG-PET imaging

  • Heart rate variabilityBaseline and 12-weeks

    Calculated from the average resting HRV collected at baseline and post-treatment visits